EP 213: Inside the science of hearing loss and gene therapy for deafness with Ellen Reisinger of the University of Tübingen

<p>This week on The Genetics Podcast, Patrick is joined by Dr. Ellen Reisinger, Professor and group leader at the University of Tübingen. They discuss her journey into hearing loss research, why otoferlin has become a leading target for gene therapy, and the emerging science shaping the next generation of treatments.</p><p><strong>Show Notes: </strong></p><p><strong>0:00 </strong>Intro to The Genetics Podcast</p><p><strong>00:59</strong> Welcome to Ellen</p><p><strong>01:52</strong> Ellen’s career path that coincidentally led to her work on otoferlin-related hearing loss</p><p><strong>03:22 </strong>Mechanism and advantages of the dual adenoassociated virus (AAV) system </p><p><strong>05:35</strong> The genetic landscape of early-onset hearing loss and why otoferlin stands out</p><p><strong>07:42</strong> Why otoferlin-related deafness is an ideal target for postnatal gene therapy development</p><p><strong>09:53 </strong>Potential next gene therapy targets beyond otoferlin and associat...